Analysis of Jaguar Health share price

67% of retail investor accounts lose money when trading CFDs with this provider.
Chart provided by Tradingview

Are you considering trading Jaguar Health shares online or buying the stock as part of your portfolio? If so, you need to make sure you have all the information you need to analyze it. In this article, we offer you data about this company and its economic environment, such as details of its activities and sources of income, its main competitors and partners on the market, and elements to follow as part of your fundamental analysis of this stock.

Elements that can influence the price of this asset:

Analysis N°1

We will have to keep an eye on the various research and development projects carried out by the group with the aim of diversifying its product portfolio and thus reaching a wider audience.

Analysis N°2

Jaguar Health's collaborations with other companies, particularly in the pharmaceutical sector, will also require your attention, and we will be watching with interest for strategic research and marketing partnerships.

Analysis N°3

Of course, you will also need to look at the Jaguar Health Group's direct competitors and their activities and developments in order to anticipate changes in the distribution of market share.

Analysis N°4

It will be important to keep an eye on the Jaguar Health Group's development strategy and communications to its shareholders regarding strategic developments and growth objectives.

Analysis N°5

Finally, it is also important to take note of the company's quarterly and annual results and compare them with the targets set and analysts' expectations.

67% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro

General presentation of Jaguar Health

In order to help you perform good analysis of Jaguar Health stock, we now offer a detailed presentation of this company. It is essential to understand how this company generates revenue in order to anticipate any changes in its growth over the long term.

Jaguar Health Inc. is an American company operating in the pharmaceutical sector. More specifically, the company specializes in the natural products segment.

In more detail, Jaguar Health specializes in the development and sale of new, sustainably derived gastrointestinal products for both humans with prescription drugs and animals. These products are marketed worldwide.

In addition, through its subsidiary Napo Pharmaceuticals Inc., the group focuses on the development and commercialization of gastrointestinal pharmaceuticals for humans and the global market. These products are based on plants that are traditionally used in tropical forest areas.

Among the leading products developed by the group is Mytesi, an antidiarrheal prescribed to relieve the symptoms of non-infectious diarrhea in adult patients suffering from HIV or Human Immunodeficiency Virus or AIDS or Acquired Immune Deficiency Syndrome and on antiretroviral therapy. Its product portfolio also includes treatments such as Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

The group currently employs 34 people.

Analysis of Jaguar Health share price
67% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro

The major competitors of Jaguar Health

Now that you are more familiar with the Jaguar Health Group's activities, we would like to tell you more about its industry environment, including an overview of its main competitors in the sector.

GW Pharmaceuticals

This British pharmaceutical company is listed on the Nasdaq as well as the London Stock Exchange and is a laboratory that has a license in England for the development of medicines based on cannabinoid medicine. Currently, it is one of the leading producers of medical cannabis in the world.

Lexicon Pharmaceuticals Inc

This company is a biopharmaceutical company that develops treatments for human diseases. Specifically, the group has advanced several drug candidates into human clinical trials and has a large and diverse pipeline of drug targets behind its clinical programs. The group is pursuing drug targets in 5 major therapeutic areas including oncology, gastroenterology, immunology, metabolism and ophthalmology.

Anatara Lifesciences

Finally, the Anatara Lifesciences group is an Australian company specialising in the development of oral solutions for gastrointestinal diseases in livestock and humans, but also develops and markets a non-antibiotic therapy to prevent and treat diarrhoea in piglets. A similar version of this treatment is also being developed for humans. The group collaborates with various pharmaceutical and biotechnology companies for the clinical development and sale of products for human and animal applications.

The major partners of Jaguar Health

Jaguar Health has many enemies in its industry, but fortunately it has some strategic allies to help boost profitability and growth. Here is a specific example of a strategic partnership that Jaguar Health has recently put in place:

Knight Therapeutics

In 2018, the group notably teamed up with Knight Therapeutics, a pharmaceutical company in Canada specializing in the acquisition, licensing, sale and marketing of innovative prescription and over-the-counter pharmaceutical products. The agreement is a distribution, licensing and supply agreement providing Knight with the exclusive right to market Mytesi and related products in the Canadian and Israeli markets and the right of first negotiation for the marketing of Mytesi and related products in certain Latin American countries. Mytesi has been approved by the FDA in the United States and is indicated for the relief of symptoms of non-infectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Jaguar is following up on potential follow-on indications for this treatment in cancer treatment-related diarrhea, rare diseases of infants and children with congenital diarrhea disorders and short bowel syndrome, as well as for irritable bowel syndrome or IBS and as a supportive treatment for inflammatory bowel disease or as a second-generation antisecretory agent for patients treated for cholera.

67% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on eToro

Frequently Asked Questions

What analysis should you use to anticipate changes in Jaguar Health stock?

While there are different types of analysis that investors use to try to anticipate changes in the Jaguar Health share price, it is important not to settle for just one, but to increase your chances of getting good signals by using several analyses together, such as technical analysis and fundamental analysis, and to compare the indications obtained by these two methods.

How do you make a coherent financial analysis of Jaguar Health?

Among the analyses that it is important to carry out before trading the Jaguar Health share, one finds in particular the financial analysis. This analysis is based on the study of the group's financial results but also and above all on their evolution over time as well as on the comparison of these actual results with the analysts' forecasts and the objectives possibly fixed by the group itself in the framework of its strategy. These results can be found on the Jaguar Health website.

Is it possible to trade Jaguar Health shares on the downside?

While most stock market investment products from banks and brokers today do not allow you to short Jaguar Health shares, you can still trade the stock down using derivatives such as CFDs or contracts for difference. These contracts replicate the price of the stock and allow you to take both a buy and sell position.

eToro is a multi-asset platform offering both equity as well as asset trading in the form of CFDs.

Please note that CFDs are complex instruments and present a high risk of rapid loss of funds due to their leverage effect. 67% of retail traders' accounts lose funds when trading CFDs with this supplier. You should ask yourself if you understand how CFDs work and if you can afford to take the significant risk of losing your money.

The content in question is provided for information purposes only and should not be considered as investment advice. Past performance is no guarantee of future results. The trading history is less than 5 years old and may not be sufficient to serve as a basis for an investment decision.

Crypto-actives are volatile instruments that can fluctuate considerably over a very short period of time and are therefore not suitable for all investors. Other than through CFDs, crypto-active trading is not regulated by any EU regulatory framework and is therefore not supervised. This is an advert for trading CFDs on eToro